Edition:
United States

OvaScience Inc (OVAS.OQ)

OVAS.OQ on NASDAQ Stock Exchange Global Market

0.97USD
22 Feb 2018
Change (% chg)

$-0.00 (-0.16%)
Prev Close
$0.97
Open
$0.97
Day's High
$1.00
Day's Low
$0.96
Volume
57,904
Avg. Vol
81,046
52-wk High
$2.05
52-wk Low
$0.91

Latest Key Developments (Source: Significant Developments)

OvaScience Says Provided Intrexon Corp With Written Notice Of Termination Of Exclusive Channel Collaboration Agreement, Dated Dec 18, 2013
Thursday, 1 Feb 2018 05:18pm EST 

Feb 1 (Reuters) - OvaScience Inc ::OVASCIENCE SAYS PROVIDED INTREXON CORP WITH WRITTEN NOTICE OF TERMINATION OF EXCLUSIVE CHANNEL COLLABORATION AGREEMENT, DATED DEC 18, 2013-SEC FILING.OVASCIENCE INC - PURSUANT TO TERMS OF OVATURE ECC, TERMINATION IS EFFECTIVE 90 DAYS FOLLOWING NOTICE.OVASCIENCE INC - "DO NOT EXPECT THE TERMINATION OF THE OVATURE ECC TO HAVE A MATERIAL IMPACT ON OUR PROGRESS".  Full Article

Ovascience Says ‍Reducing Headcount By Approximately 50 Percent​
Wednesday, 3 Jan 2018 04:06pm EST 

Jan 3 (Reuters) - Ovascience Inc ::OVASCIENCESM ANNOUNCES CORPORATE UPDATE.OVASCIENCE INC - ‍REDUCING HEADCOUNT BY APPROXIMATELY 50 PERCENT​.OVASCIENCE INC - ‍MAJORITY OF REDUCTION IN PERSONNEL IS EXPECTED TO BE COMPLETED BY MARCH 2018​.OVASCIENCE INC - JAMES LILLIE JOINING AS CHIEF SCIENTIFIC OFFICER.OVASCIENCE INC - ‍AS A RESULT OF REDUCTION IN PERSONNEL, CO EXPECTS TO REALIZE ANNUALIZED COST SAVINGS BEGINNING IN Q2 OF 2018​.OVASCIENCE INC - ‍ESTIMATES THAT IT WILL INCUR ONE-TIME COSTS OF APPROXIMATELY $1.0 MILLION TO $1.5 MILLION RELATED TO RESTRUCTURING PLAN​.OVASCIENCE INC - ‍PLANS TO INITIATE A MULTI-CENTER, PROSPECTIVE, CONTROLLED, PHASE 1B/2A CLINICAL TRIAL OF OVAPRIME​.OVASCIENCE INC - ‍EXPECTS TO BEGIN PATIENT ENROLLMENT IN FIRST HALF OF 2018 AND TO REPORT INITIAL CLINICAL DATA IN 2019​ FROM PLANNED OVAPRIME TRIAL.  Full Article

Ovascience reports Q3 loss per share $0.26
Thursday, 2 Nov 2017 04:02pm EDT 

Nov 2 (Reuters) - Ovascience Inc :Ovascience reports third quarter 2017 financial results.Q3 loss per share $0.26.Q3 earnings per share view $-0.40 -- Thomson Reuters I/B/E/S.Ovascience Inc - ‍expects to incur additional cash outlays related to restructurings of between $1.0 million and $1.5 million over 2017 and 2018​.Ovascience Inc - ‍anticipates that it will have sufficient funds without additional financing to support its operations into q1 of 2020​.  Full Article

Ovascience Q2 loss per share $0.51
Thursday, 3 Aug 2017 04:02pm EDT 

Aug 3 (Reuters) - Ovascience Inc :Ovascience reports second quarter 2017 financial results.Q2 loss per share $0.51.Q2 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S.Ovascience Inc - ‍as of June 30, 2017, Ovascience had cash, cash equivalents and short-term investments of $86.6 million​.Ovascience Inc - ‍expect total one-time cash expenditures resulting from two restructurings to be between $8 and $9 million over 2017 and 2018​.Ovascience Inc - ‍anticipates that it will have sufficient funds, without additional financing, to support its operating plan into Q1 of 2020​.  Full Article

Ovascience expects $3.5-$4.5 mln in one-time cash items related to June 2017 restructuring
Wednesday, 21 Jun 2017 04:21pm EDT 

June 21 (Reuters) - Ovascience Inc -:Anticipates $3.5 million to $4.5 million in one-time cash items related to June 2017 restructuring - sec filing.  Full Article

OvaScience appoints Christopher Kroeger as CEO
Wednesday, 21 Jun 2017 04:01pm EDT 

June 21 (Reuters) - OvaScience Inc ::OvaScience appoints Christopher Kroeger, M.D., M.B.A., as chief executive officer.Will restructure its organization, including reducing its workforce by approximately 50 percent.Says it will discontinue ongoing efforts related to augment treatment outside of North America.OvaScience Inc - upon Kroeger's transition to OvaScience, Michelle Dipp plans to step down as executive chairman, will serve as an advisor to company.OvaScience Inc says restructuring will enable company to extend its cash position into Q1 of 2020.Christophe Couturier, company's chief financial officer, is stepping down.OvaScience - Richard Aldrich, co-founder of ovascience, who has been on board of directors since 2011, will continue to serve as lead independent director.Jonathan Gillis will assume couturier's responsibilities.Expects its operating cash burn for 2017 to be lower than previously indicated.OvaScience Inc - says will have sufficient funds to support its revised operating plan into Q1 of 2020.  Full Article

Ovascience reports Q1 loss per share $0.42
Tuesday, 9 May 2017 04:02pm EDT 

May 9 (Reuters) - Ovascience Inc :Ovascience reports first quarter 2017 financial results.Q1 loss per share $0.42.Q1 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S.  Full Article

Ecor1 Capital Llc reports a 9.9 pct passive stake in Ovascience as of march 23 - SEC Filing
Friday, 31 Mar 2017 04:51pm EDT 

Ovascience Inc :Ecor1 Capital LLC reports a 9.9 percent passive stake in Ovascience Inc as of March 23, 2017 - SEC Filing.  Full Article

Ovascience reports Q4 loss per share $0.64
Thursday, 2 Mar 2017 04:06pm EST 

Ovascience Inc : Ovascience reports fourth quarter and year-end 2016 financial results . Q4 loss per share $0.64 . Q4 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S . Q4 revenue $121,000 versus I/B/E/S view $114,000 .Ovascience Inc says cash position expected to support operations into q1 2019.  Full Article

Ovascience Inc to reduce its workforce by 30 pct
Wednesday, 21 Dec 2016 04:04pm EST 

Ovascience Inc : Ovascience Inc - to continue to make augment available to patients at partner clinics in Canada and Japan and maintain its current commercial footprint . Changes will enable company to extend its cash position into Q1 of 2019 . Improving cost structure through corporate restructuring; extending cash runway to Q1 2019 . Ovascience Inc- Michelle Dipp, executive chair will oversee operations while company conducts a comprehensive search for a new chief executive officer . Also incur further restructuring charges related to restructuring plan . Ovascience - will slow commercial expansion, reassess its ongoing and planned clinical studies of augment, and undertake a corporate restructuring . Chief executive officer, Harald Stock and chief operating officer, Paul Chapman to step down to seek new opportunities . Ovascience Inc- company will also reduce its workforce by approximately 30 percent . Anticipates that operating cash burn will be between $45 million and $50 million in 2017, excluding one-time cash items . Ovascience Inc - anticipates it will have sufficient funds, without additional financing, to support its revised operating plan into Q1 of 2019 .Ovascience announces business update.  Full Article

BRIEF-OvaScience Says Provided Intrexon Corp With Written Notice Of Termination Of Exclusive Channel Collaboration Agreement, Dated Dec 18, 2013

* OVASCIENCE SAYS PROVIDED INTREXON CORP WITH WRITTEN NOTICE OF TERMINATION OF EXCLUSIVE CHANNEL COLLABORATION AGREEMENT, DATED DEC 18, 2013-SEC FILING